脂肪組織における熱産生:アドレナリン作動性および非アドレナリン作動性経路
Md Arafat Hossain1, Ankita Poojari1, Atefeh Rabiee1
1Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA.
Cells
|January 28, 2026
まとめ
肥満管理には、従来の経路を超えた新しい戦略が必要です。このレビューでは、安全で効果的なエネルギー消費のための非アドレナリン作動性標的と介入を検討し、持続的な体重管理に希望を提供します。
科学分野:
- 代謝研究
- 脂肪組織生物学
- 肥満治療
背景:
- 肥満は、エネルギーバランスの不均衡によって引き起こされる世界的な流行です。
- 褐色脂肪組織(BAT)とベージュ脂肪組織は、非震性熱産生(NST)を介してエネルギー消費(EE)を促進します。
- 古典的なアドレナリン作動性経路は、肥満治療におけるヒトへの翻訳的成功が限定的です。
研究 の 目的:
- 熱産生の活性化のための代替、非アドレナリン作動性経路をレビューすること。
- これらの経路を標的とする薬理学的および非薬理学的介入を評価すること。
- げっ歯類とヒトの肥満研究の間の翻訳ギャップを埋めること。
主な方法:
- 代替熱産生メカニズムに関する包括的な文献レビュー。
- Gタンパク質共役受容体(GPCR)、イオンチャネル、およびホルモンシグナル伝達の分析。
- 寒冷暴露、運動、食事、および新しい薬理学的薬剤を含む介入の評価。
主要な成果:
- TGR5、GLP-1R、SERCAモジュレーターなどの非アドレナリン作動性経路は、有望な代替手段を提供します。
- UCP1非依存性メカニズムと基質の無駄なサイクルが熱産生に寄与します。
- アドレナリン作動性および非アドレナリン作動性アプローチを組み合わせた多峰性療法が可能性を示しています。
結論:
- 非アドレナリン作動性およびUCP1非依存性メカニズムは、ヒトの熱産生にとって重要です。
- 効果的な肥満管理には、多様な治療戦略の統合が鍵となります。
- 将来の研究では、持続的なEEのための多峰性および組織特異的なアプローチに焦点を当てるべきです。
関連する概念動画
Adrenergic Agonists: Therapeutic Uses
1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Adrenergic Neurons: Neurotransmission
5.3K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.3K
Adrenergic Agonists: Therapeutic Classification
1.6K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.6K
Adrenergic Receptors (Adrenoceptors): Classification
4.9K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.9K
Adrenergic Receptors: ɑ Subtype
2.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.9K
Adrenergic Receptors: β Subtype
3.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.7K


